Exact FDA event identifier

Event 81316

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: September 25, 2018
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: RXQ Compounding LLC

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

Lidocaine 1% + Epinephrine 1:100,000 (MDV) INJ SOL, 50 mL per glass vial, Rx only, 340 West State Street, Unit 9, Athens, OH 45701. NDC 7073197450

D-0130-2019

Recall number: D-0130-2019
Initiated: September 25, 2018
Classification: Class II
Status: Terminated
Recalling firm: RXQ Compounding LLC
Quantity: 395 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent drug: During testing of the retention sample, the firm discovered that the product was sub-potent.

Code information

Lot# 04042018:58, Exp 10/17/18

Distribution pattern

U.S.A. nationwide